INDICAL Bioscience

INDICAL Bioscience provides validated molecular and immunological diagnostic workflows—including sample prep kits, PCR assays/qPCR assays/ELISAs/devices—for rapid identification of animal pathogens. Their technologies support early detection/prevention/monitoring of infectious diseases in livestock/poultry/pets to protect both animal and human health. INDICAL Bioscience stands out as an independent leader within veterinary molecular/immunological diagnostics following its demerger from QIAGEN’s veterinary division. Now part of the publicly traded Vimian Group AB family since at least mid–2021, it continues expanding its portfolio through acquisitions like AFOSA/Svanova while maintaining strong innovation focus across automated sample prep/extraction systems (“IndiMag”), advanced pathogen-specific PCR/qPCR assays (“virotype”), serology/immunoassay solutions (“SVANOVIR”, “AFOSA”) and digital point-of-care tools (“OvaCyte”). Its mission centers on improving both animal/human health by enabling rapid identification/prevention/control of infectious diseases worldwide—a critical role given that most emerging human infections originate from animals.